Company news
Genmab A/s (OMXCOP:GMAB) news
Every Genmab A/s press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Notice to Convene an Extraordinary General Meeting of Genmab A/S
September 8, 2026
Genmab A/S : Interim Report for the First Half of 2026
August 6, 2026
Genmab Announces Financial Results for the First Half of 2026
August 6, 2026
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
July 15, 2026
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Tr...
July 6, 2026
Genmab A/S : has published its Articles of Association
June 17, 2026
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Ritux...
June 11, 2026
Major Shareholder Announcement
May 8, 2026
Genmab Announces Financial Results for the First Quarter of 2026
May 7, 2026
Genmab A/S Share Capital Reduction
April 17, 2026
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
April 14, 2026
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
April 13, 2026
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
April 1, 2026
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab
March 19, 2026
Passing of Genmab A/S’ Annual General Meeting
March 19, 2026
Completion of Share Buy-back Program
March 16, 2026
Transactions in Connection with Share Buy-back Program
March 9, 2026
Correction to Company Announcement No. 13 of March 2, 2026
March 2, 2026
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
February 27, 2026
Genmab to Participate in Upcoming Investor Conferences
February 25, 2026
Capital Increase in Genmab as a Result of Employee Warrant Exercise
February 24, 2026
Notice to Convene the Annual General Meeting of Genmab A/S
February 18, 2026
Genmab Announces Initiation of Share Buy-Back Program
February 17, 2026
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
February 17, 2026
Genmab Publishes 2025 Annual Report
February 17, 2026
Grant of Restricted Stock Units and Warrants to Employees in Genmab
January 29, 2026
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
January 21, 2026
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refract...
January 16, 2026
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
January 7, 2026
Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Genmab Portfolio Prioritization Update
December 29, 2025
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
December 12, 2025
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
December 11, 2025
BillionToOne Appoints Anthony Pagano to Board of Directors as Audit Committee Chair
December 9, 2025
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patie...
December 8, 2025
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination...
December 7, 2025
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Dif...
December 6, 2025
Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes
December 3, 2025
Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami
November 24, 2025
Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Seni...
November 18, 2025
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administra...
November 18, 2025
Medicxi Announces €500 Million Fund V
November 14, 2025
Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured N...
November 10, 2025
Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term ...
November 10, 2025
Genmab Announces Financial Results for the Nine Months of 2025
November 6, 2025
Genmab to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference in London
November 5, 2025
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
November 3, 2025
Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.
October 21, 2025
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated...
October 18, 2025
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025
October 14, 2025